Drug & supplement interaction

Levilactobacillus Brevis + Bosutinib

Bosutinib brand name: Bosulif.

No Known Interaction
Medically reviewed by · Updated July 2026 · Pair last verified Sep 20, 2026
The bottom line No known interaction

We found no known interaction between Levilactobacillus Brevis and Bosutinib in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the label for Bosutinib states a food rule worth keeping to, and the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Facebook Post Reddit Email
On this page
Interaction report

Levilactobacillus Brevis and Bosutinib

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Bosutinib and Levilactobacillus Brevis in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Levilactobacillus Brevis safety at a glance

Levilactobacillus... overall Use caution Generally well tolerated in healthy people, but people who are seriously ill or immunocompromised should be cautious.
Pregnancy Use caution Not enough reliable safety data; talk to your doctor before using during pregnancy.
Breastfeeding Use caution Limited data on use while breastfeeding; check with your doctor or pharmacist first.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Bosutinib and Levilactobacillus Brevis? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
How we checked

Why No Interaction Is Listed for Bosutinib

Interactions in our licensed database are recorded against drug classes, not just single drug names. Bosutinib is filed under 4 classifications — including nephrotoxic drugs, hepatotoxic drugs, cytochrome p450 3a4 (cyp3a4) substrates. Levilactobacillus Brevis has documented interactions with 1 drug class — the most serious being antibiotic drugs (moderate) — and none of Bosutinib’s classifications are among them.

Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.

Keep it in perspective

Levilactobacillus Brevis Does Interact With Other Medications

Levilactobacillus Brevis has 182 moderate known drug interactions in our database — Bosutinib isn’t one of them. If you take anything else, check it against the full list below.

Moderate 182 No known interaction 2,648 (incl. Bosutinib)
Taking anything else?

Check Another of Your Medications Against Levilactobacillus Brevis

Covers the 2,830 medications we’ve checked against Levilactobacillus Brevis. Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Levilactobacillus Brevis and Bosutinib May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do. One of them is worth acting on rather than waiting out — marked below.

  • A higher chance of infection Worth acting on Additional detail

    Levilactobacillus Brevis

    “Since Levilactobacillus brevis preparations contain live and active microorganisms, there is some concern that they might cause pathogenic infection in some patients. Some lactobacilli species have been isolated in cases of bacteremia, sepsis, splenic abscess, endocarditis, necrotizing fasciitis, pancreatic necrosis, and meningoencephalitis.”

    Levilactobacillus Brevis · Natural Medicines adverse-effect record, reported in sepsis.

    1 source cited
    1. 107543. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed

    Bosutinib

    Listed in the ADVERSE REACTIONS section of the FDA label for Bosutinib. Read the label on DailyMed ›

  • Diarrhea / Nausea reported in 23.2% of FDA reports for Bosutinib Additional detail

    Levilactobacillus Brevis

    “Orally, taking Levilactobacillus brevis has rarely caused nausea, abdominal fullness, or mild diarrhea, in clinical research.”

    Levilactobacillus Brevis · Natural Medicines adverse-effect record, reported in diarrhea.

    2 sources cited
    1. 110959. Tasli L, Mat C, De Simone C, Yazici H. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6.
    2. 110962. Silva NLNV, Della Bona A, Cardoso M, et al. Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial. Orthod Craniofac Res. 2021;24(3):379-385.

    Bosutinib

    Listed in the ADVERSE REACTIONS section of the FDA label for Bosutinib, and in voluntary FDA adverse-event reports. Read the label on DailyMed ›

Effects for Bosutinib come from the ADVERSE REACTIONS section of its FDA label; effects for Levilactobacillus Brevis come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 8,931 voluntary FDA FAERS reports for Bosutinib that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

How to take them

Some Bosutinib Products Have a Food Rule — Levilactobacillus Brevis Should Not Break It

At least one FDA label for a product containing Bosutinib says to take it with food. If you take Levilactobacillus Brevis on an empty stomach out of habit, keep them separate — and take Bosutinib with a meal where the label says to.

This may not be true of your version. Food instructions belong to the product, not the ingredient: two Bosutinib products can carry different directions, and extended-release forms often differ from immediate-release ones. The label we read is quoted below — check the directions on your own box or bottle, or ask your pharmacist, for how to take the exact product you were given.

Adult patients with newly-diagnosed chronic phase Ph+ CML: 400 mg orally once daily with food.

From the Dosage and Administration section of the FDA label we read for Bosutinib — where that label names a specific product, the instruction is that product's. Read the label on DailyMed ›

A food rule is not an interaction — it is about how much of the medicine you absorb. The directions that came with your own product, and your pharmacist, outrank anything on this page.

Everything else you take

See Every Supplement That Interacts With Bosutinib

This page covers Levilactobacillus Brevis only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Bosutinib page lists 172 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Activated Charcoal (major), Asarabacca (major), Beer (major), Grapefruit (major) and Siberian Cocklebur (major).

By severity: 7 major · 126 moderate · 39 minor.

From our pharmacist’s overview on the Bosutinib page

“Grapefruit is the first thing to know about if you take bosutinib (Bosulif) for chronic myeloid leukemia. Bosutinib is cleared by the enzyme CYP3A4, and grapefruit blocks that pathway, so drug levels climb and side effects with them.”

Reviewed by 2 · Jul 18, 2026

Open the Bosutinib interaction page

How much people look this up

Where Levilactobacillus Brevis and Bosutinib Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Levilactobacillus Brevis
Steady interest

#1,098 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Bosutinib
Steady interest

#1,695 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Levilactobacillus Brevis reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 20, 2026. The Levilactobacillus Brevis and Bosutinib records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Levilactobacillus Brevis

What is Levilactobacillus Brevis?

  • Digestive health
  • Gut microbiome support
  • Immune support
  • Oral and dental health
  • Vaginal health

Levilactobacillus brevis (formerly Lactobacillus brevis) is a lactic acid bacterium found in fermented foods like sauerkraut, pickles, and kimchi, and is used as a probiotic. Early research suggests possible benefits for gut and immune health, but strong human evidence is still limited. It is generally well tolerated in healthy people, but anyone with a weakened immune system or serious illness should talk to a doctor first.

Levilactobacillus brevis · Lactobacillaceae · Whole live bacteria (probiotic strain) · Capsules, tablets, powders, fermented foods, and combination probiotic products

An interaction check asks whether these two react with each other — it does not ask whether Levilactobacillus Brevis is a good idea for someone in your situation. Here is what our Levilactobacillus Brevis record says about it on its own.

Levilactobacillus Brevis: dosing

There is no official standardized dose for Levilactobacillus brevis. Probiotic amounts are usually measured in colony-forming units (CFU), and products vary widely in strength and strain.The best approach is to follow the directions on the product label. Doses are often taken once or twice daily, sometimes with food.

From our Levilactobacillus Brevis monograph — the full record covers uses, side effects and every documented interaction.

Read the full Levilactobacillus Brevis monograph & all interactions
Medication

About Bosutinib

What Is Bosutinib Used For?

Brand name: Bosulif

Bosutinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) — a type of blood cancer. It can be used for newly diagnosed patients or for those whose cancer has stopped responding to, or who cannot tolerate, a prior treatment.

Bosulif (the brand-name product) is approved for adults and children 1 year and older with chronic phase Ph+ CML, and for adults with accelerated phase or blast phase Ph+ CML that is resistant or intolerant to prior therapy. Generic bosutinib tablets are approved for adults only with the same range of disease phases.

Most-Reported Side Effects for Bosutinib

From FAERS, the FDA’s public side-effect reporting system (8,931 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.

Diarrhea 2,071 reports
Nausea 1,015 reports
Fatigue 726 reports
Vomiting 542 reports
Rash 491 reports
See full Bosutinib drug information
Keep checking

Other Drugs & Levilactobacillus Brevis

Browse every other medication we’ve checked against Levilactobacillus Brevis — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
182Moderate
0Minor
2,647No known interaction
182 Moderate 2,647 No interaction
Moderate

182 interactions

Showing 60 of 182 moderate interactions — see all 182 on the Levilactobacillus Brevis page.

No interaction 2,647 drugs checked — show the list

We also checked Levilactobacillus Brevis against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,647 medications checked with no known interaction — see the full Levilactobacillus Brevis list.

See the full Levilactobacillus Brevis interactions page
See every supplement checked against Bosutinib, ranked by severity
Evidence & sources

Levilactobacillus Brevis References

The 4 references that drive our Levilactobacillus Brevis monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  3. Tasli L, Mat C, De Simone C, Yazici H. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6.
  4. Silva NLNV, Della Bona A, Cardoso M, et al. Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial. Orthod Craniofac Res. 2021;24(3):379-385.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Levilactobacillus Brevis and Bosutinib Together: Common Questions

Is it safe to take Levilactobacillus Brevis with Bosutinib?
We do not list a known interaction between Levilactobacillus Brevis and Bosutinib. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Levilactobacillus Brevis and Bosutinib have any of the same side effects?
Yes — our sources link each of them separately to 3 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Should I take Levilactobacillus Brevis and Bosutinib at the same time of day?
At least one FDA label for a product containing Bosutinib says to take it with food. If you take Levilactobacillus Brevis on an empty stomach out of habit, keep them separate and take Bosutinib with a meal where the label says to. Food instructions belong to the product rather than the ingredient — two Bosutinib products can differ — so check the directions on your own box. This is about absorption, not an interaction.
How was the Levilactobacillus Brevis and Bosutinib combination checked?
Interactions in our licensed database are recorded against drug classes. Bosutinib is filed under 4 classifications, and Levilactobacillus Brevis has documented interactions with 1 drug class — none of Bosutinib's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Does Levilactobacillus Brevis interact with any other medications?
Yes. Levilactobacillus Brevis has 182 documented drug interactions in our database — Bosutinib is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Bosutinib interact with any supplements?
Yes. Bosutinib has documented interactions with 172 supplements in our database — Levilactobacillus Brevis is not one of them. The Bosutinib interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Levilactobacillus Brevis monograph Uses, safety profile, and every drug interaction in one place Bosutinib drug information The full plain-English guide to this medication Bosutinib supplement interactions Every supplement checked against Bosutinib, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 4 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Bosutinib and Levilactobacillus Brevis?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.